Accretion Pharmaceuticals Limited (NSE:ACCPL)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Manufacturing and Sale of Pharmaceutical Products	898.18M	573.76M	133.53M	295.32M	225.84M
Manufacturing and Sale of Pharmaceutical Products Growth	56.54%	329.70%	-54.79%	30.76%	-
Total	898.18M	573.76M	133.53M	295.32M	225.84M
Total Growth	56.54%	329.70%	-54.79%	30.76%	-

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
India	526.12M	123.81M	293.33M	222.92M
India Growth	324.95%	-57.79%	31.58%	-
outside India	47.64M	9.72M	-	-
outside India Growth	390.31%	-	-	-
Export	-	-	517.00K	-
Total	573.76M	133.53M	293.84M	222.92M
Total Growth	329.70%	-54.56%	31.82%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 10, 2026

Data Sources Report a data error